JPMorgan and Piper Jaffray were joint bookrunning managers for deal
By Devika Patel
Knoxville, Tenn., Dec. 2 - Oxford Immunotec Global plc said the underwriters for its initial public offering of stock opted to exercise the deal's $9.65 million greenshoe in full for total proceeds of $73.97 million. The deal was announced Oct. 15 and priced for $64.32 million with the greenshoe on Nov. 22.
The company sold 6,164,000 ordinary shares at $12.00 per share. Of the shares, 804,000 were part of the fully exercised greenshoe.
J.P. Morgan Securities LLC and Piper Jaffray & Co. were the joint bookrunning managers.
Proceeds will be used to hire additional sales, marketing and customer service personnel and expand marketing programs, for research and development programs, for debt repayment, for working capital and for other general corporate purposes.
The diagnostics company is based in Abingdon, England. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "OXFD."
| Issuer: | Oxford Immunotec Global plc
|
| Issue: | Ordinary stock
|
| Amount: | $73,968,000 (including $9,648,000 greenshoe)
|
| Shares: | 6,164,000
|
| Price: | $12.00
|
| Warrants: | No
|
| Bookrunners: | J.P. Morgan Securities LLC and Piper Jaffray & Co.
|
| Co-managers: | Cowen and Co., LLC and Robert W. Baird & Co. Inc.
|
| Announcement date: | Oct. 15
|
| Pricing date: | Nov. 22
|
| Settlement date: | Dec. 2
|
| Stock exchange: | Nasdaq: OXFD
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
